Ask AI
ADCs for NSCLC

CE / CME

A Practical Framework for Clinical Integration of ADCs Into Individualized Treatment Plans for Patients With NSCLC

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurse Practitioners/Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: August 05, 2025

Expiration: February 04, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which investigational HER3-targeting ADC has shown durable antitumor response in a phase II trial that included patients with advanced EGFR-mutated NSCLC after previous treatment with an EGFR TKI and platinum-based chemotherapy?

2.

Based on the guidelines, how would you manage grade 1 mucositis associated with datopotamab deruxtecan?

3.

Which of the following genomic alterations is actionable with an approved ADC and you would test for in your patients with metastatic NSCLC?

4.

Patient Case: Patient With Advanced NSCLC



  • A 65-year-old male with a remote history of smoking presents with persistent cough, weight loss, and RUQ pain

  • Imaging reveals a lung mass, liver lesions, and bone lesions; all CT abnormalities are positive on PET/CT

  • A biopsy of the liver lesion confirms lung adenocarcinoma (TTF-1 and Napsin A positive)

  • Tissue NGS shows the presence of a HER2 exon 20 insertion; PD-L1 = 60%

  • He was treated with a platinum doublet and immunotherapy; after initial response lasting 6 mo, he now shows progression in the liver

  • Patient has a PS score of 1, mildly elevated liver enzymes, and no other comorbidities 

Which therapy would you recommend?